Skip to main content
. Author manuscript; available in PMC: 2011 Oct 26.
Published in final edited form as: Circulation. 2010 Oct 11;122(17):1690–1699. doi: 10.1161/CIRCULATIONAHA.109.912642

Table 1.

Baseline characteristics by assigned treatment and randomization strata for BARI 2D patients with follow-up health status data

Insulin Sensitization (n=1080) Insulin Provision (n=1083) Revascularization (n=1059) Medical Therapy (n=1104) CABG-Intended
PCI-Intended
Revascularization (n=342) Medical Therapy (n=359) Revascularization (n=717) Medical Therapy (n=745)
Age (years) 62.3 62.3 62.2 62.4 62.7 63.3 61.9 61.9
Male (%) 70.4 70.9 70.7 70.6 74.6 78.3 68.9 66.8
Current Smoking (%) 12.6 11.8 12.9 11.5 11.7 9.8 13.4 12.4
Body Mass Index (kg/m2) 31.8 31.7 31.6 31.9 30.0 30.8 32.4 32.5
Prior Myocardial Infarction (%) 32.4 30.9 30.5 32.7 33.5 39.6 29.0 29.4
History of Heart Failure (%) 5.7 6.7 6.6 5.8 4.7 3.4 7.6 6.9
Angina (%)
 None 38.5 40.9 37.8 41.5 33.6 42.9 39.8 40.8
 Stable CCS I/II 43.4 42.6 41.8 44.2 42.1 47.6 41.6 42.6
 Stable CCS III/IV or Unstable 18.1 16.5 20.4 14.3 24.3 9.5 18.6 16.6
Duration of Diabetes (years) 10.0 10.6 10.1 10.6 10.0 10.8 10.1 10.4
Insulin Use (%) 26.7 28.4 26.7 28.4 20.5 24.0 29.7 30.5

DASI (score, 0–58.2) 18.9 19.3 19.1 19.1 17.4 19.4 19.9 18.9
Energy (score, 0–100) 52.1 51.6 51.2 52.5 56.4 59.2 48.8 49.3
Health Distress (score, 0–100) 40.1 40.6 40.7 40.0 38.5 33.9 41.8 42.9
Self-rated Health (score, 0–100) 39.2 38.5 39.5 38.3 39.6 39.6 39.4 37.6